

12 July 2016

The Manager **Company Announcements** Australian Securities Exchange Ltd Level 5, 20 Bridge Street Sydney NSW 2000

Dear Sir/Madam

#### **Appendix 3B**

Please find attached an Appendix 3B in respect of the issue of 300,000 ordinary fully paid shares on the exercise of unlisted options.

**Dacian Gold Limited** 

**Kevin Hart** 

**Company Secretary** 

A.C.N: 154 262 978 A.B.N: 61 154 262 978

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

## Appendix 3B

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Dacia	Jacian Gold Limited		
ABN	262 OF 8		
01 154	262 978		
We (t	he entity) give ASX the followin	g information.	
	1 - All issues ast complete the relevant sections (attack)	ch sheets if there is not enough space).	
1	*Class of *securities issued or to be issued	Ordinary fully paid shares	
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	300,000	
3	Principal terms of the *securities (eg, if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)		

Name of entity

<sup>+</sup> See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?  If the additional securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	Yes
5	Issue price or consideration	\$0.83 per share
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Shares issued on the exercise of unlisted options exercisable at \$0.83 each and expiring 9 October 2017.
6a	Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?	Yes
	If Yes, complete sections 6b – 6h <i>in relation to the *securities the subject of this Appendix 3B</i> , and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	16 November 2015
6c	Number of *securities issued without security holder approval under rule 7.1	Nil
6d	Number of *securities issued with security holder approval under rule 7.1A	Nil

Appendix 3B Page 2 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Nil	
6f	Number of securities issued under an exception in rule 7.2	300,000	
6g	If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.	N/a	
6h	If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/a	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Yes	
7	Dates of entering *securities into uncertificated holdings or despatch of certificates	12 July 2016	
		Number	+Class
8	Number and *class of all *securities quoted on ASX (including the securities in section 2 if applicable)	133,606,254	Ordinary fully paid shares (DCN)

<sup>+</sup> See chapter 19 for defined terms.

9 Number and \*class of all \*securities not quoted on ASX (including the securities in section 2 if applicable)

Number	<sup>+</sup> Class
5,400,000	Options exercisable at \$0.83 each and expiring 9 October 2017.
500,000	Options exercisable at \$0.56 each and expiring 28 February 2019.
1,000,000	Options exercisable at \$0.64 each and expiring 24 September 2019.
2,000,000	Options exercisable at \$0.45 each and expiring 17 November 2019.
1,500,000	Options exercisable at \$1.21 each and expiring 30 September 2020.
1,650,000	Options exercisable at \$1.22 each and expiring 31 January 2021.
300,000	Options exercisable at \$2.05 each and expiring 28 February 2021.
500,000	Options exercisable at \$3.72 each and expiring 30 June 2021.

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

N/a			

Appendix 3B Page 4 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

### Part 2 - Bonus issue or pro rata issue

11	Is security holder approval required?	N/a
12	Is the issue renounceable or non-renounceable?	N/a
13	Ratio in which the *securities will be offered	N/a
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	N/a
15	<sup>+</sup> Record date to determine entitlements	N/a
16	Will holdings on different registers (or subregisters) be aggregated for calculating	N/a
	entitlements?	
17	Policy for deciding entitlements in relation to fractions	N/a
18	Names of countries in which the entity has *security holders who will not be sent new issue documents	N/a
	Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
	Cross reference. rate 7.7.	
19	Closing date for receipt of acceptances or renunciations	N/a
	N C 1	
20	Names of any underwriters	N/a
21	Amount of any underwriting fee or commission	N/a
22	Names of any brokers to the issue	N/a
23	Fee or commission payable to the broker to the issue	N/a
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders	N/a
	behalf of 'security holders	

<sup>+</sup> See chapter 19 for defined terms.

25	If the issue is contingent on <sup>†</sup> security holders' approval, the date of the meeting	N/a
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	N/a
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/a
28	Date rights trading will begin (if applicable)	N/a
29	Date rights trading will end (if applicable)	N/a
30	How do *security holders sell their entitlements <i>in full</i> through a broker?	N/a
31	How do *security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/a
32	How do *security holders dispose of their entitlements (except by sale through a broker)?	N/a
33	<sup>+</sup> Despatch date	N/a
Part 3 - Quotation of securities  You need only complete this section if you are applying for quotation of securities		
34	Type of securities (tick one)	
(a)	Securities described in Part	1
(b)	*	nd of the escrowed period, partly paid securities that become fully paid, en restriction ends, securities issued on expiry or conversion of convertible

Appendix 3B Page 6 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

#### Entities that have ticked box 34(a)

#### Additional securities forming a new class of securities

o indicate you are providing the information or ents	
If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders	
If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories  1 - 1,000  1,001 - 5,000  5,001 - 10,000  10,001 - 100,000  100,001 and over	
A copy of any trust deed for the additional *securities	
es that have ticked box 34(b)	
Number of securities for which †quotation is sought N/a	
Class of *securities for which quotation is sought N/a	
Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?  If the additional securities do not rank equally, please state:  • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	

<sup>+</sup> See chapter 19 for defined terms.

41	Reason for request for quotation now	N/a
	Example: In the case of restricted securities, end of restriction period	
	(if issued upon conversion of another security, clearly identify that other security)	

42 Number and \*class of all \*securities quoted on ASX (including the securities in clause 38)

Number	+Class
N/a	

#### **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.

Appendix 3B Page 8 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 12 July 2016

Company secretary

Print name: Kevin Hart

== == == ==

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B – Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for +eligible entities

Introduced 01/08/12

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue	96,100,000	
Add the following:		
Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2	21,841,254 ordinary fully paid shares issued pursuant to an accelerated non-renounceable entitlement offer, comprising:  - 11,665,578 shares (11/11/2015); and  - 10,175,676 shares (1/12/2015).  Ordinary fully paid shares issued on the exercise of options:	
<ul> <li>Number of fully paid ordinary securities issued in that 12 month period with shareholder approval</li> <li>Number of partly paid ordinary securities that became fully paid in that 12 month period</li> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot</li> </ul>	- 300,000 (5/5/2016) - 650,000 (20/6/2016) - 300,000 (12/7/2016)	
<ul> <li>be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
<b>Subtract</b> the number of fully paid ordinary securities cancelled during that 12 month period	Nil	
"A"	119,191,254	

<sup>+</sup> See chapter 19 for defined terms.

Appendix 3B Page 10 01/08/2012

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
<b>Multiply</b> "A" by 0.15	17,878,688	
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used		
<b>Insert</b> number of equity securities issued or agreed to be issued in that 12 month period not counting those issued:	14,415,000 shares issued pursuant to a share placement to institutional and sophisticated investors (11/11/2015)	
Under an exception in rule 7.2		
Under rule 7.1A		
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>		
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"C"	14,415,000	
Step 4: Subtract "C" from ["A" x "B"] to ounder rule 7.1	calculate remaining placement capacity	
"A" x 0.15	17,878,688	
Note: number must be same as shown in Step 2		
Subtract "C"	14,415,000	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"	3,463,688	
	[Note: this is the remaining placement capacity under rule 7.1]	

<sup>+</sup> See chapter 19 for defined terms.

#### Part 2

Rule 7.1A – Additional placement capacity for eligible entities  Step 1: Calculate "A", the base figure from which the placement capacity is calculated	
Note: number must be same as shown in Step 1 of Part 1	
Step 2: Calculate 10% of "A"	
"D"	0.10
	Note: this value cannot be changed
<b>Multiply</b> "A" by 0.10	11,919,125
Step 3: Calculate "E", the amount of place already been used	ement capacity under rule 7.1A that has
<b>Insert</b> number of equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	Nil
<ul> <li>Notes:</li> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	
"E"	Nil

Appendix 3B Page 12 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	11,919,125
Note: number must be same as shown in Step 2	
Subtract "E"	Nil
Note: number must be same as shown in Step 3	
<b>Total</b> ["A" x 0.10] – "E"	11,919,125
	Note: this is the remaining placement capacity under rule 7.1A

<sup>+</sup> See chapter 19 for defined terms.